Medicine and Health

Prolonged response to first-generation tyrosine kinase inhibitor in a metastatic non-small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review

K. H. Do, D. T. Le, et al.

Discover a remarkable case from Vietnam where a patient with metastatic non-small cell lung cancer experienced an unprecedented response of over 44 months to gefitinib treatment, despite harboring rare EGFR mutations. This study, authored by Kien Hung Do and colleagues, sheds light on the need for further research in targeting such mutations effectively.

00:00

Playback language: English

Index

Abstract

This case report from Vietnam details a patient with metastatic non-small cell lung cancer (NSCLC) harboring rare EGFR compound mutations (G719X and S768I) who showed a prolonged response (over 44 months) to first-line gefitinib treatment. The patient experienced a significant reduction in symptoms and tumor size, with no serious adverse events. This case, along with a literature review, highlights the inconsistent response to TKIs for this rare mutation and suggests the need for further research.

Publisher

Respirology Case Reports

Published On

Jan 01, 2023

Authors

Kien Hung Do, Duc Thanh Le, Tai Van Nguyen, Tu Anh Do, Chu Van Nguyen

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer

Y. Zeng, C. Hu, et al.

Medicine and Health

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial

T. Sonoda, Y. Umeda, et al.

Medicine and Health

A huge primary adenoid cystic carcinoma of the lung: case report and review of the literature

Z. Laklaai, K. Chanoune, et al.

Medicine and Health

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

S. Mukherjee, C. N. Hurt, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny